Related Experiment Videos
Evaluation of D-penicillamine in juvenile chronic arthritis. A double-blind, multicenter study
Insights
D-penicillamine effectively treats joint pain and stiffness in juvenile chronic arthritis. This study found D-penicillamine improved symptoms and reduced the need for other medications, with good tolerability in children.
Area of Science:
- Pediatric Rheumatology
- Pharmacology
Background:
- Juvenile chronic arthritis (JCA) is a significant rheumatologic condition in children.
- Current treatments aim to manage inflammation and preserve joint function.
Purpose of the Study:
- To evaluate the efficacy and safety of D-penicillamine in treating juvenile chronic arthritis.
- To compare D-penicillamine's effects against a placebo over a 6-month period.
Main Methods:
- A 6-month, multicenter, double-blind, placebo-controlled study.
- Involved 74 children diagnosed with juvenile chronic arthritis.
- Evaluated outcomes including joint stiffness, pain, severity index, and medication use.
Main Results:
- Significant improvement in joint stiffness, pain, and overall severity index observed.
- Reduced need for nonsteroidal anti-inflammatory drugs in the D-penicillamine group.
- D-penicillamine was well-tolerated, with only 2 patients discontinuing treatment due to adverse effects.
- Relapses were more common in the placebo group.
Conclusions:
- D-penicillamine demonstrates significant efficacy in managing joint involvement in juvenile chronic arthritis.
- The drug is well-tolerated and offers a viable treatment option for pediatric patients.
- Results support the use of D-penicillamine for long-term joint health in JCA.
Abstract:
Seventy-four children with juvenile chronic arthritis were entered into a 6-month, multicenter, comparative double-blind study of the efficacy of D-penicillamine versus placebo. The results were evaluated in 70 patients, 55 of whom completed 6 months of the study. Improvement was observed in the total number of stiff joints, total number of painful joints, and total severity index measuring joint pain. There was also a significant reduction in the concurrent use of nonsteroidal anti-inflammatory drugs. D-penicillamine was well-tolerated in all but 2 patients. Some children in the placebo group exhibited definite improvement; however, relapses that were observed were mainly in that group. These results confirm the efficacy of D-penicillamine for the treatment of joint involvement in juvenile chronic arthritis.